Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hatchtech has concluded treating patients in a Ha02-003 Phase 2b double-blind, placebo controlled, randomized, vehicle-controlled trial investigating the safety, efficacy and tolerability of two dose levels of a single application of DeOvo compared to vehicle.
Subscribe to our email newsletter
The trial involves around 132 healthy subjects with head lice infestation, 2 years of age and older, in two study centers in the US.
DeOvo, a topical formulation of a known metalloprotease inhibitor, has shown both ovicidal and lousicidal activity and offered the potential for a more effective treatment following a single application.
Hatchtech chairman Paul Kelly said they continue to be encouraged by Hatchtech’s progress with its next generation head lice product DeOvo in line with their business objectives. T
"he recruitment and treatment of subjects in this study has been achieved and we look forward to receiving results of the study later this year as planned," Kelly said.